NCT03318900: A reported trial by M.D. Anderson Cancer Center
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03318900 |
|---|---|
| Title | Phase I/Ib Study of Adoptive Cellular Therapy Using Autologous IL-21-Primed CD8+ Tumor Antigen-Specific T Cells in Combination With Utomilumab (PF-05082566) in Patients With Platinum Resistant Ovarian Cancer |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 4, 2018 |
| Completion date | Dec. 20, 2023 |
| Required reporting date | Dec. 19, 2024, midnight |
| Actual reporting date | Sept. 5, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |